Table 1.
Patient Characteristics at Enrollment According to Treatment Group
| Characteristic | All Patients (N = 68) | S Group (n = 20) | S + E Group (n = 18) | E Group (n = 30) |
|---|---|---|---|---|
| Age, yrs | 65 ± 11 | 59 ± 12 | 66 ± 8 | 68± 11 |
| ABI | 0.69 ± 0.14 | 0.68 ± 0.15 | 0.64 ± 0.14 | 0.72 ± 0.13 |
| Body mass index, kg/m2 | 29 ± 6 | 27± 5 | 28± 6 | 31± 6 |
| Male | 38 (56) | 14 (70) | 11 (61) | 13 (43) |
| Previous lower extremity revascularization | 12 (18) | 3 (15) | 4 (22) | 5 (17) |
| Leg of interest | 9 (13) | 3 (15) | 2 (11) | 4 (13) |
| Race | ||||
| White | 49 (72) | 14 (70) | 13 (72) | 22 (73) |
| Black | 15 (22) | 5 (25) | 4 (22) | 6 (20) |
| Native American | 4 (6) | 1 (5) | 1 (6) | 2 (7) |
| Risk factors | ||||
| Tobacco use | 30 (44) | 10 (50) | 12 (67) | 8 (27) |
| Diabetes mellitus | 22 (32) | 5 (25) | 7 (39) | 10 (33) |
| Hypertension | 58 (85) | 17 (85) | 13 (72) | 28 (93) |
| History of CAD | 42 (62) | 13 (65) | 11 (61) | 18 (60) |
| Hypercholesterolemia | 50 (73) | 11 (55) | 11 (61) | 28 (93) |
| Medications | ||||
| Aspirin/clopidogrel | 47 (69) | 14 (70) | 11 (61) | 22 (73) |
| ACE inhibitor | 31 (46) | 8 (40) | 6 (33) | 17 (57) |
| ARB | 9 (13) | 4 (20) | 3 (17) | 2 (7) |
| Beta-blocker | 29 (43) | 8 (40) | 7 (39) | 14 (47) |
| Cilastazol | 8 (12) | 2 (10) | 3 (17) | 3 (10) |
Values are mean ± SD or n (%). There were no differences in any demographic parameters in the S and S + E groups.
ABI = ankle-brachial index; ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; E group = study group treated with usual statin and open-label ezetimibe added; S group = study group treated with simvastatin; S + E group = study group treated with simvastatin + ezetimibe.